Results 191 to 200 of about 1,272,638 (236)

ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2. [PDF]

Endocr Relat Cancer
Kavanagh DO, McIlroy M, Myers E, Bane F, Crotty TB, McDermott E, Hill AD, Young LS.   +7 more
europepmc   +1 more source

Lipid droplet profiling during neutrophil differentiation by stimulated Raman scattering microscopy

Biotechnology Progress, EarlyView.
Abstract Lipid droplets (LDs) are dynamic organelles that serve as metabolic hubs and emerging regulators of immune cell fate. Although LDs have been implicated in immune regulation, how LD metabolism is remodeled during neutrophil differentiation and how stage‐specific LD dynamics shape mature neutrophil function remain poorly defined.
Ting‐Jung Sung, Bin Dong, Jingqiao Shen, Yan Tan, Chi Zhang, Xiaoping Bao   +5 more
wiley   +1 more source

Effect of Diosgenin in Suppressing Viability and Promoting Apoptosis of Human Prostate Cancer Cells: An Interplay with the G Protein-Coupled Oestrogen Receptor? [PDF]

Int J Mol Sci
Figueira MI, Marques R, Cardoso HJ, Fonseca LRS, Duarte AP, Silvestre S, Socorro S.   +6 more
europepmc   +1 more source

Increased Insulin Action, Glucose Metabolism and Muscle Function in Supervillin‐Knockout and Supervillin‐Mutant Mice

Cytoskeleton, EarlyView.
ABSTRACT We here describe mouse models with complementary homozygous Svil mutations. In skeletal muscle, Svil‐Mut mice express the Svil‐encoded N‐terminus fused to the βgal‐neo gene‐trap tag and lack the highly conserved archvillin C‐terminus; Svil‐KO mice lack expression of all known Svil‐encoded proteins; and Svil‐LoxP mice contain loxP sites for ...
Tara C. Smith, Lauren A. Tauer, Randall H. Friedline, Xiaodi Hu, Duy Tran, Yangyi E. Luo, Nacima Hadjout‐Rabi, Elisabeth R. Barton, Jason K. Kim, Elizabeth J. Luna   +9 more
wiley   +1 more source

Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance. [PDF]

Mol Oncol
Albrecht J, Müller M, Hafstað V, Kaminska K, Vallon-Christersson J, Honeth G, Persson H.   +6 more
europepmc   +1 more source

Biography as the Missing Variable in Drug Development: A Case for Bio‐Biographical Mechanistic Profiling

Clinical Pharmacology &Therapeutics, EarlyView.
Most clinical trial failures reflect unmeasured biological heterogeneity. Biography — chronic stress, adversity, trauma, and social isolation—is a neglected source of that heterogeneity, operating through the same molecular pathways drugs engage.
Ralph I. Horwitz
wiley   +1 more source

Corrigendum to "Low cytoplasmic NUB1 protein exerts hypoxic cell death with poorer prognosis in oestrogen receptor negative breast cancer patients" [Translational Oncology, volume 49 (2024), 102106]. [PDF]

Transl Oncol
Tan KL, Haider S, Zois CE, Hu J, Turley H, Leek R, Buffa F, Acuto O, Harris AL, Pezzella F.   +9 more
europepmc   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai, Anton L V Avanceña, Juan P Cata, Jamie C. Barner, Sharon H. Giordano, Chanhyun Park, Hui Zhao, Kirk E. Evoy, John K. Lin, Jennifer C. Spencer, Mariana Chavez‐MacGregor, Kelly K. Hunt, Kerollos Nashat Wanis   +12 more
wiley   +1 more source

Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling. [PDF]

Clin Transl Immunology
van Houtum EJ, Valk AH, Granado D, Lok J, van den Bogaard L, Remkes N, van Eck van der Sluijs J, Span PN, Cornelissen LA, Adema GJ.   +9 more
europepmc   +1 more source

Creatinine–Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib

Clinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib increases serum creatinine by inhibiting renal tubular transporters rather than reducing true glomerular filtration rate, a phenomenon known as pseudo‐acute kidney injury. Creatinine–cystatin C discrepancy and genetic determinants of this elevation remain insufficiently characterized in Japanese patients.
Hiroaki Watanabe, Keita Hirai, Takaaki Oba, Mayu Ono, Ken‐ichi Ito, Takafumi Naito   +5 more
wiley   +1 more source